|1.||Cummins, James E: 3 articles (05/2008 - 11/2005)|
|2.||Paull, Jeremy R A: 2 articles (06/2011 - 07/2005)|
|3.||Dezzutti, Charlene S: 2 articles (05/2007 - 11/2005)|
|4.||Guenthner, Patricia C: 2 articles (05/2007 - 11/2005)|
|5.||Paxton, Lynn: 2 articles (05/2007 - 11/2005)|
|6.||Grohskopf, Lisa A: 2 articles (05/2007 - 11/2005)|
|7.||Guarner, Jeannette: 2 articles (05/2007 - 11/2005)|
|8.||Nandy, Bidisha: 1 article (11/2015)|
|9.||Dixit, Narendra M: 1 article (11/2015)|
|10.||Saurabh, Suman: 1 article (11/2015)|
12/01/2003 - "From these studies a lead compound and formulation (2V of SPL7013) was chosen for ongoing evaluations in primate models of simian immunodeficiency virus and Chlamydia trachomatis infection."
06/01/2011 - "In addition, the mode of action by which SPL7013 prevents infection of cells with X4 and R5X4 strains is likely to differ from R5 strains of HIV-1."
05/01/2006 - "However, a single intravaginal application of the 3% (wt/wt) SPL7013 gel did not provide protection from the acquisition of cervical chlamydial infection."
07/01/2005 - "Using Starpharma's work on the prevention of HIV and sexually transmitted infections (STIs) through the development of microbicide candidates as an example, the process from which SPL7013 emerged as a development candidate is described. "
05/01/2008 - "PRO 2000 and SPL7013 (the active component of VivaGel), two microbicide products currently being evaluated in human clinical trials, were tested in this in vitro algorithm and were shown to be highly active against CCR5- and CXCR4-tropic HIV-1 infection."
|5.||Herpes Genitalis (Genital Herpes)
12/01/2003 - "Unformulated SPL7013 provided significant protection from genital herpes disease and infection at concentrations as low as 1 mg/ml and for at least 1 h following topical (intravaginal) administration of 10 mg/ml. This compound was then formulated into three vehicles and further evaluated in mouse and guinea pig models of genital herpes infection. "
|1.||PRO 2000 (PRO-2000)
|3.||Nonoxynol (Nonoxynol 9)